Compare Immunovant Inc. Common Stock (IMVT) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs VF Corp — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while VF Corp trades at $14.52 (market cap $5.65B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and VF Corp pays a 2.5% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and VF Corp for 64 Days on average.
| IMVT | VFC | |
|---|---|---|
Market Cap | $6.62B | $5.65B |
Volume | 1,131,364 | 6,542,273 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $21.55 |
52-Week Low | $17.03 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $5.72B | $9.94B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VFC trades at $14.53, up 0.55% with a bullish technical signal from moving averages. The company reported mixed quarterly results, beating in Q4 2025 but missing in subsequent quarters. Revenue declined from $11.8B in 2022 to $9.5B in 2025, with net losses in recent years. Analyst consensus shows 41% buy ratings with an $18.33 price target, while the stock faces execution risks from Vans brand weakness despite stronger Outdoor segment performance.
The outlook remains cautious with valuation appearing reasonable (P/E 20.84, P/S 0.6) but dependent on successful turnaround execution. Key risks include persistent Vans weakness, high debt levels, and competitive pressures. Upside potential exists if management can stabilize revenue and improve profitability, but investors face significant execution uncertainty in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
